CN103110645A - Cefminox sodium drug composition and preparation method thereof - Google Patents
Cefminox sodium drug composition and preparation method thereof Download PDFInfo
- Publication number
- CN103110645A CN103110645A CN2013100739682A CN201310073968A CN103110645A CN 103110645 A CN103110645 A CN 103110645A CN 2013100739682 A CN2013100739682 A CN 2013100739682A CN 201310073968 A CN201310073968 A CN 201310073968A CN 103110645 A CN103110645 A CN 103110645A
- Authority
- CN
- China
- Prior art keywords
- metronidazole
- injection
- pharmaceutical composition
- cefminox sodium
- lipid microsphere
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention provides a cefminox sodium drug composition and a preparation method thereof, relating to the fields of pharmaceutical preparations and preparation methods and mainly solving the problems that single preparations of cefminox sodium and metronidazole in the prior art have great dosages, poor treatment effects after being combined and big side effects. The drug composition comprises cefminox sodium and metronidazole lipid microspheres in a weight ratio of (100:3)-(100:10), wherein the weight of the metronidazole lipid microspheres is based on metronidazole. The drug composition is prepared into powder injection. The pH value of water solution of the drug composition is 6.5-7.0. The powder injection of the drug composition provided by the invention not only has high curative effect but also can reduce the dosage of metronidazole by over 80%, thus greatly reducing or avoiding the toxic and side effects, especially gastrointestinal reactions including nausea, emesis, anorexia, abdominal cramp and neurotoxicity, of metronidazole and further reducing the occurrence rate of adverse reactions.
Description
Technical field:
The present invention relates to pharmaceutical preparation and preparation method field, relate in particular to a kind of cefminox sodium pharmaceutical composition and preparation method thereof.
Background technology:
Its chemical name of Cefminox sodium is: (6R, 7S)-7 β-[(S)-2-[(2-amino-2-carboxyethyl) sulfur] acetylamino]-7 α-methoxyl group-3-[1-methyl isophthalic acid H-tetrazolium-5-yl) methyl]-8-oxygen-5-thia-1-azabicyclo [4.2.0] oct-2-ene-2-formic acid sodium salt.Molecular formula: C
16H
20N
7NaO
7S
3, molecular weight: 541.56.Its chemical structural formula is:
Cefminox sodium is not only to the bacterial multiplication phase, and the stable phase initial stage is also brought into play bactericidal action.Cefminox sodium is also to show the cephamycin-type preparation of bactericidal action under passivating conditions in propagation, and bacterial multiplication phase and stable phase are all shown antibacterial action, lower than MIC concentration, bactericidal action is arranged also, bacteriolyze in the short time.The antimicrobial spectrum that comprises anaerobe is all applicable.Cefminox sodium all has antibacterial activity more widely to G-, G+, and the strain that the daily recall rates such as escherichia coli, bacillus canalis capsulatus, hemophilus influenza, Proteus are higher and the Bacteroides of anaerobe show very strong antimicrbial power.In addition, extremely stable to various bacteriogenic beta-lactamases.
1972, Tally found that first metronidazole has the effect of whole body anaerobe resistant, and was defined as the drug of first choice of anti anaerobic bacteria infection by World Health Organization (WHO) in 1978.In clinical extensive use, its purposes is widened day by day along with metronidazole, and its advantage is: the scope of anaerobe resistant is wide, and sterilizing power is strong, general avirulence, and side reaction is few, has no drug resistance.It has tablet, injection, suppository, compound preparation, can be for oral, quiet notes and anus plug, also can be applied to intravenously administrable with other multiple antibacterials preparation, so, the requisite a kind of curative of clinical departments become.Recently studying its mechanism of action is, answers by its reduzate and bacterial cell DNA antisense, disturbs growth, the breeding of antibacterial, last kill bacteria.
infection in clinical operation usually is accompanied by the mixed infection that contains anaerobe and aerobe, rather than the infection of single anaerobe or aerobe, it is the clinical first-selected medication for the treatment of anaerobic infection because of metronidazole, Cefminox sodium commonly used and metronidazole drug combination contain the MOI of anaerobe for preventing post-operation infection and treatment clinically, but cefminox sodium for injection and injection metronidazole are all single product preparations, during the difference medication, the consumption of metronidazole is very large, the toxic and side effects of metronidazole is very strong, the metronidazole of normal therapeutic dosage can produce digestive tract reaction, the most common comprise nauseating, vomiting, inappetence, abdominal colic and higher neurotoxicity.To this for clinical provide a kind of safe and effective, medicine that toxic and side effects is low is extremely urgent, Given this, proposes the present invention.
Summary of the invention:
Technical problem to be solved by this invention is to overcome the defective of prior art, provide a kind of curative effect high, safe, good stability, the cefminox sodium pharmaceutical composition that toxic and side effects is low, this pharmaceutical composition principal agent is: Cefminox sodium and metronidazole lipid microsphere, said composition can effectively be treated the MOI that contains anaerobe.
Technical problem to be solved by this invention realizes by the following technical solutions.
A kind of cefminox sodium pharmaceutical composition, it is characterized in that, this pharmaceutical composition comprises Cefminox sodium and metronidazole lipid microsphere, the weight ratio of Cefminox sodium and metronidazole lipid microsphere is 100:3-100:10, the weight of metronidazole lipid microsphere is in metronidazole, this pharmaceutical composition is prepared into powder ampoule agent for injection, and the pH value of the aqueous solution of this pharmaceutical composition is 6.5-7.0.
In this pharmaceutical composition, the preferred weight ratio of Cefminox sodium and metronidazole lipid microsphere is 100:5, and the weight of metronidazole lipid microsphere is in metronidazole, and the preferred pH value of the aqueous solution of this pharmaceutical composition is 6.5-6.8.
Another object of the present invention is to provide a kind of method that cefminox sodium pharmaceutical composition is prepared into powder ampoule agent for injection, it is characterized in that, the concrete steps of the method are:
(1) preparation metronidazole lipid microsphere, this goods mean diameter is less than 120 nm, and pH value is between 6.5-6.8, and the absolute value of Zeta-potential is greater than 20 mV, and envelop rate is more than 80%.
The crude drug component of preparation metronidazole lipid microsphere is:
The step of preparation metronidazole lipid microsphere is:
A) glycerol for injection and the poloxamer F-68 with recipe quantity is dissolved in water for injection, be placed in 80 ℃ of water bath with thermostatic control magnetic stirring apparatuss and be stirred to whole dissolvings, make mixture A, the injection water yield can be with abundant fused the getting final product of glycerol for injection and poloxamer F-68;
B) recipe quantity oleic acid is added in the oil phase that is consisted of by long-chain fat acid glyceride and medium chain length fatty acid triglyceride, forms and mix oil phase;
C) fabaceous lecithin and the metronidazole with recipe quantity adds in dehydrated alcohol 200ml, is stirred to fabaceous lecithin and metronidazole under 80 ℃ all after dissolving, and decompression volatilizes dehydrated alcohol, then adds the mixing oil phase, stirs and makes mixture B;
D) mixture A is added in mixture B, be placed in the 8000r/min of high-speed tissue mashing machine and stir 3 times, each 3min;
E) regulate pH value to 6.5-6.8, water for injection is settled to 1000ml, adds in high pressure homogenizer 70MPa homogenizing 8 times;
F) bottling, gland, 100 ℃ of sterilization 30min, the rapid cooling of ice-water bath and get final product, standby;
(2) with the metronidazole lipid microsphere of recipe quantity, directly be added in the water for injection of recipe quantity, the injection water yield can be dissolved the metronidazole lipid microsphere fully and be got final product;
(3) after stirring and dissolving the pH value of regulator solution in the 6.5-6.8 scope;
(4) and then by 0.45 μ m, 0.22 μ m filter membrane carry out the degerming circulating filtration, 30 minutes time;
(5) after pick test meets the requirements, solution is divided be filled in the rustless steel pallet, enter freeze drying box, carry out lyophilization and process, obtain the aseptic freeze-dried powder of metronidazole lipid microsphere, pulverize and sieve;
(6) metronidazole lipid microsphere lyophilized powder and the Cefminox sodium sterilized powder after pulverizing and sieving is mixed in proportion, and after pick test meets the requirements, carries out packing according to labelled amount, namely gets required powder ampoule agent for injection.
The specification that described cefminox sodium pharmaceutical composition is prepared into powder ampoule agent for injection is 0.5g/ bottle and 1.0g/ bottle, and quality is in cefminox.
Pharmaceutical composition preparation technology of the present invention is simple, has guaranteed well the growth of related substance in the storage of the stability of active component and finished product.
The present invention is directed to treatment clinically and contain the MOI of anaerobe and propose, a kind of cefminox sodium for injection composition powder injection is provided.The every consumption per day of Cefminox sodium list product preparation adult is 2g clinically, and the consumption that metronidazole list product preparation is grown up every day is the 2g left and right.in cefminox sodium pharmaceutical composition provided by the invention, Cefminox sodium, metronidazole lipid microsphere (take metronidazole) weight ratio (W/W) is 100:3-100:10, therefore the every consumption per day of Cefminox sodium is 2g, when dividing the secondary administration, the consumption of metronidazole every day is 60mg-400mg, each consumption is 30mg-100mg, be that 4000ml calculates by the normal adult total blood volume, after each administration, blood drug level is 7.5-25 μ g/ml, and the metronidazole effective blood drug concentration is 2-8 μ g/ml, the metronidazole lipid microsphere has slow releasing function, the effective blood drug concentration time can keep more than 12 hours in vivo.Pharmaceutical composition powder pin provided by the invention not only has high curative effect thus, and can reduce metronidazole consumption (using more than 80% less), thereby greatly alleviate or avoided the toxic and side effects of metronidazole, digestive tract reaction particularly, comprise nauseating, vomiting, inappetence, abdominal colic and neurotoxicity, more reduced the incidence rate of untoward reaction.
The specific embodiment:
For technological means, creation characteristic that the present invention is realized, reach purpose and effect is easy to understand, below in conjunction with specific embodiment, further set forth the present invention.
For the concordance of guarantee test result, the embodiment of the present invention has been used raw material, adjuvant, cillin bottle and the plug of same batch, and has adopted consistent production technology to prepare the cefminox sodium pharmaceutical composition powder pin of injection.
Embodiment one, cefminox sodium for injection composition powder injection are in 1000
Prescription (specification: the 0.5g/ bottle):
Preparation technology:
Metronidazole lipid microsphere (in metronidazole) with recipe quantity directly is added in appropriate water for injection; Add the pH value of pH adjusting agent regulator solution to make it in the 6.5-6.8 scope after stirring and dissolving; Carry out the degerming circulating filtration, 30 minutes time by 0.45 μ m, 0.22 μ m filter membrane again; After pick test meets the requirements, solution is divided be filled in the rustless steel pallet, enter freeze drying box, carry out lyophilization and process, obtain the aseptic freeze-dried powder of metronidazole, pulverize and sieve; After the metronidazole lyophilized powder after pulverizing and sieving and the mixing of Cefminox sodium sterilized powder, after pick test meets the requirements, carry out packing according to labelled amount, namely get required sample.
Embodiment two, cefminox sodium for injection composition powder injection are in 1000
Prescription (specification: the 1.0g/ bottle):
Preparation technology:
Metronidazole lipid microsphere (in metronidazole) with recipe quantity directly is added in appropriate water for injection; Add the pH value of pH adjusting agent regulator solution to make it in the 6.5-6.8 scope after stirring and dissolving; Carry out the degerming circulating filtration, 30 minutes time by 0.45 μ m, 0.22 μ m filter membrane again; After pick test meets the requirements, solution is divided be filled in the rustless steel pallet, enter freeze drying box, carry out lyophilization and process, obtain the aseptic freeze-dried powder of metronidazole, pulverize and sieve; After the metronidazole lyophilized powder after pulverizing and sieving and the mixing of Cefminox sodium sterilized powder, after pick test meets the requirements, carry out packing according to labelled amount, namely get required sample.
Clinical data
In the patient who makes a definite diagnosis anaerobe and aerobe (to the aerobe of Cefminox sodium sensitivity) mixed infection, use A scheme (2 bottles/day of cefminox sodium for injection composition powder injections (1.0g/ bottle)) and B scheme (Cefminox sodium 2.0g/ day+metronidazole 2g/ day) GP TH, each is organized and divides equally 2 venoclysises every day, its curative effect and untoward reaction are as follows: to curative effect judgement terminal point, total number of cases 150 examples of A scheme group, effective 143 examples, total effective rate is 95.3%, total number of cases 150 examples of B scheme group, effective 134 examples, total effective rate are 89.3%.
Adverse effect
Treat in 300 routine cases, the untoward reaction of varying degree appears in totally 17 examples, the side effect incidence rate is 5.67%, wherein gastrointestinal reaction appears in the routine patient of A scheme group 5, the side effect incidence rate be 3.33%, B scheme group totally 12 examples the untoward reaction of varying degree appears, the side effect incidence rate is 8.00%, show as the stomach burn feeling, feel sick, erythra etc.A scheme group adverse reaction rate and degree are all lower than B scheme group.
Above demonstration and described ultimate principle of the present invention, principal character and advantage of the present invention.The technical staff of the industry should understand; the present invention is not restricted to the described embodiments; what describe in above-described embodiment and description is only preference of the present invention; be not used for limiting the present invention; without departing from the spirit and scope of the present invention; the present invention also has various changes and modifications, and these changes and improvements all fall in the claimed scope of the invention.The claimed scope of the present invention is defined by appending claims and equivalent thereof.
Claims (4)
1. cefminox sodium pharmaceutical composition, it is characterized in that, this pharmaceutical composition comprises Cefminox sodium and metronidazole lipid microsphere, the weight ratio of Cefminox sodium and metronidazole lipid microsphere is 100:3-100:10, the weight of metronidazole lipid microsphere is in metronidazole, this pharmaceutical composition is prepared into powder ampoule agent for injection, and the pH value of the aqueous solution of this pharmaceutical composition is 6.5-7.0.
2. cefminox sodium pharmaceutical composition according to claim 1, it is characterized in that, in this pharmaceutical composition, the preferred weight ratio of Cefminox sodium and metronidazole lipid microsphere is 100:5, the weight of metronidazole lipid microsphere is in metronidazole, and the preferred pH value of the aqueous solution of this pharmaceutical composition is 6.5-6.8.
3. the described pharmaceutical composition of claim 1 or 2 is prepared into the method for powder ampoule agent for injection, it is characterized in that, the concrete steps of the method are:
(1) preparation metronidazole lipid microsphere
The crude drug component of preparation metronidazole lipid microsphere is:
The step of preparation metronidazole lipid microsphere is:
A) glycerol for injection and the poloxamer F-68 with recipe quantity is dissolved in water for injection, be placed in 80 ℃ of water bath with thermostatic control magnetic stirring apparatuss and be stirred to whole dissolvings, make mixture A, the injection water yield can be with abundant fused the getting final product of glycerol for injection and poloxamer F-68;
B) recipe quantity oleic acid is added in the oil phase that is consisted of by long-chain fat acid glyceride and medium chain length fatty acid triglyceride, forms and mix oil phase;
C) fabaceous lecithin and the metronidazole with recipe quantity adds in dehydrated alcohol 200ml, is stirred to fabaceous lecithin and metronidazole under 80 ℃ all after dissolving, and decompression volatilizes dehydrated alcohol, then adds the mixing oil phase, stirs and makes mixture B;
D) mixture A is added in mixture B, be placed in the 8000r/min of high-speed tissue mashing machine and stir 3 times, each 3min;
E) regulate pH value to 6.5-6.8, water for injection is settled to 1000ml, adds in high pressure homogenizer 70MPa homogenizing 8 times;
F) bottling, gland, 100 ℃ of sterilization 30min, the rapid cooling of ice-water bath and get final product, standby;
(2) with the metronidazole lipid microsphere of recipe quantity, directly be added in the water for injection of recipe quantity, the injection water yield can be dissolved the metronidazole lipid microsphere fully and be got final product;
(3) after stirring and dissolving the pH value of regulator solution in the 6.5-6.8 scope;
(4) and then by 0.45 μ m, 0.22 μ m filter membrane carry out the degerming circulating filtration, 30 minutes time;
(5) after pick test meets the requirements, solution is divided be filled in the rustless steel pallet, enter freeze drying box, carry out lyophilization and process, obtain the aseptic freeze-dried powder of metronidazole lipid microsphere, pulverize and sieve;
(6) metronidazole lipid microsphere lyophilized powder and the Cefminox sodium sterilized powder after pulverizing and sieving is mixed in proportion, and after pick test meets the requirements, carries out packing according to labelled amount, namely gets required powder ampoule agent for injection.
4. cefminox sodium pharmaceutical composition according to claim 3 is prepared into the method for powder ampoule agent for injection, it is characterized in that: the specification that described cefminox sodium pharmaceutical composition is prepared into powder ampoule agent for injection is 0.5g/ bottle and 1.0g/ bottle, and quality is in cefminox.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100739682A CN103110645A (en) | 2013-03-08 | 2013-03-08 | Cefminox sodium drug composition and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2013100739682A CN103110645A (en) | 2013-03-08 | 2013-03-08 | Cefminox sodium drug composition and preparation method thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN103110645A true CN103110645A (en) | 2013-05-22 |
Family
ID=48409046
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2013100739682A Pending CN103110645A (en) | 2013-03-08 | 2013-03-08 | Cefminox sodium drug composition and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN103110645A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250236A (en) * | 1991-08-05 | 1993-10-05 | Gasco Maria R | Method for producing solid lipid microspheres having a narrow size distribution |
-
2013
- 2013-03-08 CN CN2013100739682A patent/CN103110645A/en active Pending
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5250236A (en) * | 1991-08-05 | 1993-10-05 | Gasco Maria R | Method for producing solid lipid microspheres having a narrow size distribution |
Non-Patent Citations (4)
| Title |
|---|
| L.A.M. FERREIRA ET AL: "Vehicle influence on in vitro release of metronidazole:role of w/o/w multiple emulsion", 《INTERNATIONAL JOURNAL OF PHARMACEUTICS》 * |
| YUTAKA MIZUSHIMA: "Lipid microspheres (lipid emulsions) as a drug carrier - An overview", 《ADVANCED DRUG DELIVERY REVIEW》 * |
| 冯大林等: "脂质微球给药系统的研究进展", 《现代医药卫生》 * |
| 李莉: "头孢米诺钠在甲硝唑、替硝唑注射液中的稳定性考察", 《中国药师》 * |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2124972B1 (en) | Use of a composition made of mineral nutrients and optionally acetogenic and/or butyrogenic bacteria in order to avoid or reduce the formation of gas in the large intestine of a mammal and the resulting abdominal problems | |
| CN103005168A (en) | Microbial lysozyme microcapsule as well as preparation and application of microbial lysozyme microcapsule | |
| CN104543668A (en) | Inulin composition and preparation method thereof | |
| CN102552293B (en) | Compound vitamin submicron emulsion lyophilized powder for injection and preparation method of compound vitamin submicron emulsion lyophilized powder | |
| CN103142587B (en) | Amoxicillin sodium-potassium clavulanate pharmaceutical composition and preparation method thereof | |
| CN103127129A (en) | Cefuroxime sodium pharmaceutical composition and preparation method thereof | |
| CN105266162B (en) | A kind of natto capsule health food containing for having whole intestines concurrently and adjusting immunity | |
| CN101003539A (en) | Trometamol salt in compound of cillin category, and preparation method | |
| CN102614294A (en) | Compound amoxicillin suspension injection and preparation method thereof | |
| CN103110645A (en) | Cefminox sodium drug composition and preparation method thereof | |
| CN103142615A (en) | Ceftriaxone sodium pharmaceutical composition and preparation method thereof | |
| CN101756899A (en) | Valnemulin nano-emulsion antibacterial medicine preparation | |
| CN103142591A (en) | Ticarcillin sodium-potassium clavulanate pharmaceutical composition powder injection | |
| CN103110642A (en) | Cefonicid sodium drug composition and preparation method thereof | |
| CN103127130A (en) | Cefotaxime sodium pharmaceutical composition powder injection | |
| CN103142590A (en) | Ampicillin sodium-cloxacillin sodium pharmaceutical composition and preparation method thereof | |
| CN103142625A (en) | Fosfomycin sodium pharmaceutical composition and preparation method thereof | |
| CN103251552B (en) | Enrofloxacin cataplasm and preparation method thereof | |
| DE60203895T2 (en) | USE OF N-ACETYL-D-GLUCOSAMINE IN THE MANUFACTURE OF A MEDICAMENT FOR SUPPRESSING THE SIDE EFFECTS OF RADIOTHERAPY AND CHEMOTHERAPY | |
| CN103110625A (en) | Azlocillin sodium drug composition and preparation method thereof | |
| CN103142589A (en) | Mezlocillin sodium pharmaceutical composition for injection and preparation method thereof | |
| KR100980254B1 (en) | Composition for helicobactor pylori bactericide causing gastritis or peptic ulser coprising polylysine and glycerol monolaurate | |
| CN103127128A (en) | Cefpirome sulfate pharmaceutical composition powder injection | |
| CN103110643A (en) | Powder injection of drug composition of ceftazidime for injection | |
| CN103110644A (en) | Powder injection of drug composition of cefoperazone sodium and sulbactam sodium for injection |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20130522 |